Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


We create and evaluate new disease control technologies, such as digital contact tracing applications, and apply modelling and machine learning to evaluate epidemic interventions and maximise containment.

We develop and validate point of care and sequenced-based molecular tests, which can be adapted to any pathogen and setting.

We discover, optimise and evaluate new therapeutic targets through the Centre for Medicines Discovery and the Division of  Structural Biology, and advance these through academic and commercial partnerships.

We conduct pivotal clinical trials such as the RECOVERY trial and are working to extend international capabilities in platform clinical trials for endemic, epidemic and pandemic infectious diseases.

We design and evaluate new vaccines against outbreak pathogens, such as COVID-19, and develop novel vaccine technologies. We focus on affordability, scalability, and technology transfer.